Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Incorrectly Reported Request for Reply

Incorrectly Reported Request for Reply Letters holding IMBRUVICA for at least 3 to 7 days pre and post sur- Figure. Bilateral Periorbital Ecchymosis After MMS gery depending upon the type of surgery and the risk of bleeding.” While patient 2 had a history of “occasional” use of Anacin (400 mg aspirin/32 mg caffeine), it is unclear whether he had taken the drug prior to MMS. If so, this may have been an ad- ditional factor contributing to his postoperative course. Nev- ertheless, our experience highlights that it may be prudent to withhold ibrutinib treatment prior to dermatologic surgery to avoid potential bleeding complications. As our case 1 illus- trates, discontinuing ibrutinib treatment 3 days before MMS of the face can still be associated with extensive ecchymosis and hematoma formation (Figure), which suggests that with- holding ibrutinib treatment for a longer period of time may be appropriate in certain cases. Cindy E. Parra, BA Emily Newsom, MD Erica H. Lee, MD John N. Allan, MD Kira Minkis, MD, PhD Author Affiliations: Weill Cornell Medical College, New York, New York (Parra); Department of Dermatology, Weill Cornell/New York Presbyterian, New York, New York (Newsom, Minkis); Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York (Lee); http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Incorrectly Reported Request for Reply

JAMA Dermatology , Volume 153 (10) – Oct 30, 2017

Loading next page...
 
/lp/american-medical-association/incorrectly-reported-request-for-reply-fy5mpnT8pf
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2017.3036
Publisher site
See Article on Publisher Site

Abstract

Letters holding IMBRUVICA for at least 3 to 7 days pre and post sur- Figure. Bilateral Periorbital Ecchymosis After MMS gery depending upon the type of surgery and the risk of bleeding.” While patient 2 had a history of “occasional” use of Anacin (400 mg aspirin/32 mg caffeine), it is unclear whether he had taken the drug prior to MMS. If so, this may have been an ad- ditional factor contributing to his postoperative course. Nev- ertheless, our experience highlights that it may be prudent to withhold ibrutinib treatment prior to dermatologic surgery to avoid potential bleeding complications. As our case 1 illus- trates, discontinuing ibrutinib treatment 3 days before MMS of the face can still be associated with extensive ecchymosis and hematoma formation (Figure), which suggests that with- holding ibrutinib treatment for a longer period of time may be appropriate in certain cases. Cindy E. Parra, BA Emily Newsom, MD Erica H. Lee, MD John N. Allan, MD Kira Minkis, MD, PhD Author Affiliations: Weill Cornell Medical College, New York, New York (Parra); Department of Dermatology, Weill Cornell/New York Presbyterian, New York, New York (Newsom, Minkis); Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York (Lee);

Journal

JAMA DermatologyAmerican Medical Association

Published: Oct 30, 2017

References